Pfizer Inc. (NYSE:PFE) reported positive results from its Phase 3 trial for TUKYSA in treating HER2+ metastatic breast cancer, showing significant improvement in progression-free survival. The company is a global biopharmaceutical firm known for discovering and developing medicines.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing